株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

オピオイドの世界市場 - 成長、動向、予測

Opioids Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 659352
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.69円で換算しております。
Back to Top
オピオイドの世界市場 - 成長、動向、予測 Opioids Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年03月01日 ページ情報: 英文 120 Pages
概要

世界のオピオイド市場は、2018年から2023年の予測期間中に、約5.0%のCAGRで成長する見通しです。ケシから得られるオピオイド剤は、法的に製造された医薬品と違法な麻薬に大別されます。オピオイド市場は主に、緩和ケア施設の増加と疼痛管理の普及によって成長が促進されています。地域別には、オピオイドの導入が増加し、老齢人口が増加し、米国およびカナダの優れた医療施設に対する需要が増加しているため、北米は予測期間にわたって市場を支配すると見込まれています。

当レポートでは、世界のオピオイド市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場の概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品およびサービスの脅威
    • 業界内での競争

第6章 成長要因、阻害要因、機会、課題の分析(DROC)

  • 市場の成長要因
    • 整形外科的疾患および慢性疼痛の流行
    • オピオイドの即時放出から持続放出性製剤へ
    • ジェネリック医薬品メーカーによる乱用防止剤(ADF)への関心の高まり
    • 増加する緩和ケア施設
  • 市場の阻害要因
    • オピオイドの代替品としての大麻の出現と合法化
    • 処方薬の乱用
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 製品タイプ別
    • コデイン
    • フェンタニル
    • モルヒネ
    • メペリジン
    • メタドン
    • その他
  • 受容体結合別
    • 強いアゴニスト
    • 軽度から中等度のアゴニスト
    • 混合受容体反応
  • アプリケーション別
    • 疼痛管理
    • 風邪と咳
    • 下痢
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Allergan
  • Egalet Corporation
  • Endo Pharmaceuticals Inc.
  • Janssen Pharmaceuticals Inc.
  • Mallinckrodt
  • Pfizer Inc.
  • Purdue Pharma LP
  • Qrxpharma Limited
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

第10章 市場の将来展望

目次
Product Code: 61713

Market Overview

  • Opioids are considered as some of the most effective drugs for the management of pain. Moreover, their use in the management of severe pain and chronic pain, which are associated with advanced medical illness, is considered to be standard practice in most parts of the world. Due to an increase in the incidence of medical ailments, the market studied is expected to grow over the forecast period.
  • The rising occurrence of orthopedic disorders, such as arthritis, elbow pain, fibromyalgia, and osteoporosis, and the associated chronic pain, is the primary factor responsible for the growth of the opioids market. Opioids play a vital role in acute post-operative settings to provide adequate analgesia. As per the Center for Disease Control and Prevention, over 30 million patients are affected by osteoarthritis each year in the United States. There is an increasing rate of osteoarthritis in the United Kingdom. According to the Arthritis UK in 2016, approximately one in five adults over 45 years in England had osteoarthritis in knee and one in nine adults had osteoarthritis in hip, which amount to around 8.5 million people suffering from the disease. In addition, the International Osteoporosis Foundation states that osteoporosis is considered as one of the most serious public health concerns among women, affecting more than 30% of the population each year in the United States and Europe and leading to multiple fractures.
  • According to the Office of National Drug Control Policy, in 2016, opioid painkillers were the most-commonly prescribed medication in the United States. Additionally, according to a recent study published in the Archives of Internal Medicine in 2017, it was estimated that 15% to 20% of physician visits in the United States involve an opioid prescription.
  • Therefore, opioid therapy is the mainstay of orthopedic treatment of patients with moderate to severe pain, and this drives the growth of the opioid market.

Scope of the Report

According to the report, opioids are a class of drugs that act on the nervous system to reduce pain. They are primarily used for pain relief and for anesthesia. The scope of this report is limited to products tracked in the opioid market segmentation.

Key Market Trends

Strong Agonists are Expected to Hold the Largest Market Share in the Receptor Binding Segment

In the receptor binding segment of the opioids market, the strong agonist category is expected to have the largest market size. This segment is expected to witness a CAGR of 5.02% in the forecast period. An agonist is a drug that triggers certain receptors in the brain. Methadone (strong) agonist therapy is an effective treatment for addiction to opioid drugs (such as heroin). Strong agonist opioids activate opioid receptors, and after binding tightly, undergo significant conformational changes. Strong agonists include codeine, fentanyl, heroin, hydrocodone, methadone, morphine, and oxycodone. As per the US Department of Health and Human Services and National Institutes of Health, in 2015, 25.4 million Americans adults experienced pain daily. This statistic indicates the importance of pain management and impacts the opioid market positively.

North America Dominates the Market and is Expected to Continue to Dominate in the Forecast Period

North America currently dominates the market for opioids and is expected to continue its strong hold for a few more years. Codeine and morphine are the most commonly prescribed opioids for cancer patients to relieve pain. However, illegal use of fentanyl to relieve pain is rising across the United States. Recently, in 2018, despite the escalating trade war between the United States and China, medical and law enforcement officials and politicians tried to stop illegally mailed fentanyl from China to the United States. Some of the major companies in the United States market include Teva, Janssen, Insys, and Mylan. However, some of these companies have been involved in legal actions instituted against them for persuading doctors to influence sales of opioids to boost the market.

In the past two years, initiatives and campaigns have been initiated under the Centers for Disease Control and Prevention and Federal government to fight the opioid epidemic. Due to these actions, growth of the studied market is expected to steadily slow down over the forecast period.

Competitive Landscape

The opioids market consists of several players. In terms of market share, few of the players currently dominate the market. However, with the rising usage of the opioids in medicines, more companies are trying to enter this market, especially in the emerging markets. However, strict laws and stringent regulatory policies are deterring market penetration by small- and mid-sized companies. Allergan, Teva Pharmaceuticals, Mallinckrodt, Insys Therapeutics, and Amneal Pharmaceuticals Inc. hold a substantial market share of the opioids market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain
    • 4.2.2 Inclination toward Extended Release Formulations from Immediate Release of Opioids
    • 4.2.3 Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers
    • 4.2.4 Growing Palliative Care Facilities
  • 4.3 Market Restraints
    • 4.3.1 Advent and Legalization of Cannabis as an Alternative to Opioids
    • 4.3.2 Prescription Drug Abuse
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product Type
    • 5.1.1 Codeine
    • 5.1.2 Fentanyl
    • 5.1.3 Morphine
    • 5.1.4 Meperidine
    • 5.1.5 Methadone
    • 5.1.6 Other Product Types
  • 5.2 Receptor Binding
    • 5.2.1 Strong Agonist
    • 5.2.2 Mild to Moderate Agonist
  • 5.3 Application
    • 5.3.1 Pain Management
      • 5.3.1.1 Cancer Pain
      • 5.3.1.2 Neuropathic Pain
      • 5.3.1.3 Osteoarthritis Pain
      • 5.3.1.4 Other Pain Managements
    • 5.3.2 Cold and Cough
    • 5.3.3 Diarrhoea
    • 5.3.4 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan Plc
    • 6.1.2 Mallinckrodt LLC
    • 6.1.3 Purdue Pharma LP
    • 6.1.4 Rhodes Technologies LP
    • 6.1.5 Sun Pharmaceutical Industries Ltd
    • 6.1.6 Teva Pharmaceutical
    • 6.1.7 Vertice Pharma LLC
    • 6.1.8 Johnson and Johnson
    • 6.1.9 INSYS Therapeutics
    • 6.1.10 Hikma Pharmaceuticals PLC
    • 6.1.11 Endo Pharmaceuticals Inc.
    • 6.1.12 Egalet Corporation
    • 6.1.13 Amneal Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top